CLINICAL EXPERIENCE OF USE OF BEVACIZUMAB (AVASTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH UNIDENTIFIED HER2/NEW AND ER PR-RECEPTOR STATUS
- Авторлар: Konstantinova M.M.1, Shikina VE1, Makshantsev AY.1, Konstantinova MM1, Shikina VY.1, Makshantsev AY.1
-
Мекемелер:
- Шығарылым: № 7 (2011)
- Беттер: 33-36
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278857
- ID: 278857
Дәйексөз келтіру
Толық мәтін
Аннотация
Негізгі сөздер
Авторлар туралы
Mariya Konstantinova
V Shikina
A Makshantsev
M Konstantinova
V Shikina
A Makshantsev
Әдебиет тізімі
- Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-67.
- Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26:suppl; abstr LBA1011.
- Robert NJ, Dieras V, Brufsky GA, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009;27(15s):abstr 1005.
- Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: A randomized, double-blind, placebo controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER-2-negative metastatic breast cancer. SABCS December 9-13, 2009:abstr. 42.
- O'Shaughnessy J, et al. J Clin Oncol 2010;28(15s)